At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 30 enrolled
Drug / intervention
Lenvatinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1b Trial of Lenvatinib Plus Nivolumab in Subjects With Hepatocellular Carcinoma
In Brief
A Phase 1 clinical trial evaluating Lenvatinib and Nivolumab for Carcinoma, Hepatocellular. Completed, enrolled 30 participants across 6 sites.
Detailed Summary
The primary objective of this study is to evaluate the tolerability and safety of a combination of lenvatinib plus nivolumab in participants with hepatocellular carcinoma (HCC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Hepatocellular
CountriesJapan
CollaboratorsOno Pharmaceutical Co., Ltd.
Timeline
Phase 1CompletedFinished
201820192020202120222023202420252026
Enrollment StartJan 2018
First PostedFeb 2018
Primary CompletionDec 2022
TodayJul 2026
First PostedFeb 1, 2018
Enrollment StartJan 16, 2018
Primary CompletionDec 28, 2022
TodayJul 2, 2026
Enrollment to primary: 5.0 yearsPosted 8.4 years ago
Interventions
Lenvatinibdrug
Specified doses will be administered orally on specified days.
Nivolumabdrug
Specified doses will be administered intravenously on specified days.